By efrat|2024-07-16T12:38:00+00:00July 20th, 2024|All|Comments Off on July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
By efrat|2024-07-16T06:49:04+00:00July 16th, 2024|All|Comments Off on July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
By efrat|2024-07-04T15:03:17+00:00July 4th, 2024|All|Comments Off on July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
By efrat|2024-06-16T07:59:45+00:00June 23rd, 2024|All|Comments Off on June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment
By efrat|2024-06-16T07:54:57+00:00June 16th, 2024|All|Comments Off on June 17th 2024- Prof. Saad Usmani- Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma
By efrat|2024-06-06T10:12:14+00:00June 10th, 2024|All|Comments Off on June 11th 2024- Dr. Zachariah DeFilipp- Flares of Acute Graft-Versus-Host Disease: a Mount Sinai Acute GVHD International Consortium Analysis
By efrat|2024-05-29T06:46:47+00:00June 2nd, 2024|All|Comments Off on June 3rd 2024- Prof Saad Usmani- CD8 Effector T Cells Enhance Teclistamab Response in BCMA-Exposed and -Naïve Multiple Myeloma
By efrat|2024-05-21T07:05:01+00:00May 23rd, 2024|All|Comments Off on May 24th 2024- Dr. Ruth Namazzi- Hydroxyurea reduces infections in children with sickle cell anemia in Uganda
By efrat|2024-05-15T11:09:33+00:00May 19th, 2024|All|Comments Off on May 20th 2024- Dr. Lorenz Bastian- Developmental trajectories and cooperating genomic events define molecular subtypes of BCR:ABL1-positive ALL
By efrat|2024-05-09T09:19:49+00:00May 13th, 2024|All|Comments Off on May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
